NASDAQ:STRO Sutro Biopharma Q1 2025 Earnings Report $0.89 -0.02 (-1.79%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$0.89 +0.00 (+0.16%) As of 09/19/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Sutro Biopharma EPS ResultsActual EPS-$0.91Consensus EPS -$0.63Beat/MissMissed by -$0.28One Year Ago EPSN/ASutro Biopharma Revenue ResultsActual Revenue$17.40 millionExpected Revenue$11.61 millionBeat/MissBeat by +$5.79 millionYoY Revenue GrowthN/ASutro Biopharma Announcement DetailsQuarterQ1 2025Date5/8/2025TimeBefore Market OpensConference Call DateThursday, May 8, 2025Conference Call Time4:00PM ETUpcoming EarningsSutro Biopharma's Q3 2025 earnings is scheduled for Wednesday, November 12, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Sutro Biopharma Earnings HeadlinesSutro Biopharma (NASDAQ:STRO) Rating Increased to Hold at Wall Street ZenSeptember 14, 2025 | americanbankingnews.comSutro Biopharma price target lowered to $4 from $7 at JefferiesSeptember 9, 2025 | msn.comWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensuring wealth is passed on according to your wishes. Trusts may also provide shielding from creditors and lawsuits while offering potential tax advantages—especially with estate tax thresholds set to decrease in 2026. If you’re considering whether a family trust is right for you, speaking with a fiduciary financial advisor can help you decide the best path forward. We’ve created a free tool that matches you with vetted advisors in your area—each legally bound to act in your best interest. | SmartAsset (Ad)Vaxcyte Advances VAX-31 Infant Phase 2 Study with New Optimized Dose Aimed at Enhancing Immune Response Against Invasive Pneumococcal DiseaseSeptember 3, 2025 | quiverquant.comQSutro Biopharma’s STRO-002: A Promising Phase 1 Trial Update in Ovarian and Endometrial CancersAugust 20, 2025 | msn.comSutro Biopharma (STRO) Gets a Buy from Truist FinancialAugust 14, 2025 | theglobeandmail.comSee More Sutro Biopharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Sutro Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sutro Biopharma and other key companies, straight to your email. Email Address About Sutro BiopharmaSutro Biopharma (NASDAQ:STRO) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel biologic drug candidates in the fields of oncology and immunology. The company leverages a proprietary cell-free protein synthesis platform, XpressCF™, to design and produce complex, multi-specific proteins that include antibody-drug conjugates, bispecific antibodies, and cytokine fusion proteins. This platform enables rapid generation and optimization of protein therapeutics that may not be feasible with traditional cell-based expression systems. Founded in 2003 and headquartered in South San Francisco, California, Sutro Biopharma has built a pipeline of immuno-oncology candidates in various stages of preclinical and clinical development. The company’s lead programs target solid tumors and hematologic malignancies, with several assets designed to engage the immune system through both targeted delivery of cytotoxic payloads and enhancement of T-cell activity. In addition to advancing its own pipeline, Sutro has forged research and development collaborations with global pharmaceutical partners to apply its XpressCF™ platform across a range of therapeutic areas. With operations anchored in the San Francisco Bay Area, Sutro Biopharma serves both domestic and international partners through collaborative agreements and licensing arrangements. The company’s scientific leadership brings together expertise in protein engineering, antibody biology, and translational medicine, positioning Sutro to address challenging molecular targets and streamline the path from discovery to clinical testing. As a publicly traded entity on the NASDAQ under the symbol STRO, Sutro continues to pursue innovative biologic therapies aimed at improving outcomes for patients with cancer and other immune-related diseases.View Sutro Biopharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Berkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings FallRH Stock Slides After Mixed Earnings and Tariff ConcernsCelsius Stock Surges After Blowout Earnings and Pepsi DealWhy DocuSign Could Be a SaaS Value Play After Q2 EarningsWhy Broadcom's Q3 Earnings Were a Huge Win for AVGO BullsAffirm Crushes Earnings Expectations, Turns Bears into Believers Upcoming Earnings Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025)Accenture (9/25/2025)NIKE (9/30/2025)PepsiCo (10/9/2025)BlackRock (10/10/2025)Fastenal (10/13/2025)Citigroup (10/14/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
